The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.
The genetic testing firm can now offer its Prelude noninvasive prenatal test to residents in New York State.
The new funding comes from life sciences investment firm Perceptive Advisors. Home Care Assistance CEO Lily Sarafan has also joined Counsyl's board.
Under an agreement, Angsana's network of physicians in Hong Kong will be able to order Counsyl's expanded carrier screening test.
Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
The partners will commercialize Counsyl's Expanded Carrier Screening Test as preconGen, beginning in Spain, Italy, Portugal, Switzerland, and Colombia.
Sync for Genes seeks to leverage HL7 FHIR infrastructure to communicate information from clinical genomic labs in a format for universal use across medicine.
The deal adds germline mutation information to the tumor sequencing, proteomic, and phosphoproteomic data Perthera currently uses to guide patient therapy.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.